arrow
P

Philip N. Newsome

king’s college hospital
H指数:82
被引数:4.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Delphi survey to explore core curriculum for training the next generation of hepatologists

德尔菲调查探索下一代肝病学家培训的核心课程

2026-08-010
PRE
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement

代谢功能障碍相关脂肪性肝病且FIB-4与肝硬度测量结果不一致患者的组织学严重程度和肝脏结局

2026-01-011
PRE
Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease

振动控制瞬时弹性成像与组织学在预测代谢功能障碍相关脂肪性肝病相关事件中的头对头比较

2025-12-010
PRE
Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD

心血管-肾脏-代谢综合征与MASLD患者肝纤维化进展及肝脏相关事件的风险

2025-12-010
PRE
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD

长期血糖控制与肝硬度进展及肝脏相关事件风险的关系 (MASLD)

2025-10-100
PRE
Association between longitudinal weight change and clinical outcome in individuals with MASLD

MASLD个体中纵向体重变化与临床结局的关联

2025-10-012
PRE
Supplementary Material for Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data from Nine Countries

代谢功能障碍相关脂肪性肝炎(MASH)的全球临床、人文和经济影响预测项目补充资料:基于九国数据的无所作为的成本

2025-09-080
PRE
Effect of Hypertension on Long-term Adverse Clinical Outcomes and Liver Fibrosis Progression in MASLD

高血压对长期不良临床结局及MASLD患者肝纤维化进展的影响

2025-08-230
PRE
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD

纤维化标志物的纵向变化:监测MASLD的僵硬/纤维化进展和预后结局

2025-07-240
PRE
A novel risk prediction model for hepatocellular carcinoma in MASLD: A multinational, multicenter cohort study

一种新型MASLD相关肝细胞癌风险预测模型:一项跨国、多中心队列研究

2025-07-100
PRE